Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009 Bergen, Norway.
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83. doi: 10.1016/j.jneuroim.2013.08.013. Epub 2013 Aug 31.
We characterized GBM patients' tumor and systemic immune contexture with aim to reveal the mechanisms of immunological escape, their impact on patient outcome, and identify targets for immunotherapy. Increased CD3(+) T-cell infiltration was associated with prolonged survival independent of age, MGMT promoter methylation and post-operative treatment that implies potential for immunotherapy for GBM. Several mechanisms of escape were identified: within the tumor microenvironment: induced CD8(+)CD28(-)Foxp3(+) Tregs that may tolerize antigen presenting cells, elevated CD73 and CD39 ectonucleotidases that suppress T-cell function, and at the systemic level: elevated IL-10 levels in serum, diminished helper T-cell counts, and upregulated inhibitory CTLA-4.
我们对 GBM 患者的肿瘤和全身免疫结构进行了特征分析,旨在揭示免疫逃逸的机制、它们对患者预后的影响,并确定免疫治疗的靶点。CD3(+)T 细胞浸润增加与生存期延长相关,与年龄、MGMT 启动子甲基化和术后治疗无关,这意味着 GBM 可能具有免疫治疗的潜力。我们确定了几种逃逸机制:在肿瘤微环境中:诱导 CD8(+)CD28(-)Foxp3(+)Tregs,可能使抗原呈递细胞耐受;CD73 和 CD39 外核苷酸酶升高,抑制 T 细胞功能;在全身水平:血清中 IL-10 水平升高,辅助性 T 细胞计数减少,抑制性 CTLA-4 上调。